Investor Relations

Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Stock Information

Nasdaq: OASM





52 week Low/High

Day Low/High

Company Overview

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Contact Information

Investor Relations

Oasmia Pharmaceutical AB
Mikael Asp
Chief Executive Officer
Vallongatan 1
752 28, Uppsala
T: +46 18 50 54 40

Transfer Agent

Bank of New York Mellon Corporation